Entering text into the input field will update the search result below

Dynavax +9.3% after amended deal on asthma candidate

  • Dynavax (NASDAQ:DVAX) gained 9.3% after its announcement that an amendment to its collaboration deal with AstraZeneca (AZN -0.1%) means that AstraZeneca, not Dynavax, will conduct a Phase 2a trial of AZD1419 in asthma patients.
  • The safety and efficacy trial will take place this year. A previous Phase 1a study showed ascending doses of AZD1419 were well tolerated in patients.
  • The treatment is a second-generation TLR9 agonist CpG oligodeoxynucleotide formulated for inhalation use.
  • After hours today: AZN -0.8%.

Recommended For You

About DVAX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
DVAX--
Dynavax Technologies Corporation